Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 , an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
QIMC Announces Closing of $17.3 Million Bought Deal Offering, Including Full Exercise of Underwriter's Over-Allotment Option
New Found Gold Closes Bought Deal Financing Including Full Exercise of Underwriters' Over-Allotment Option for Gross Proceeds of $115M
Couloir Capital Is Pleased to Announce That It Has Initiated Research Coverage on Pinnacle Silver and Gold
